VEGFA and glioma: The results show that after treatment with anti-VEGF agent BEV there is a significant decrease in GBCA-enhancing volume, and a decrease in perfusion using ferumoxytol in the enhancing area of high grade gliomas after chemotherapy and radiation therapy but only when the pre-treatment enhancing regions of interest (ROIpre) were used.